Free Trial

Autolus Therapeutics (AUTL) Competitors

Autolus Therapeutics logo
$1.85 +0.01 (+0.54%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$1.88 +0.02 (+1.35%)
As of 08/14/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AUTL vs. AMRX, NAMS, XENE, KNSA, RXRX, CNTA, ARWR, IDYA, BHC, and BLTE

Should you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include AMNEAL PHARMACEUTICALS (AMRX), NewAmsterdam Pharma (NAMS), Xenon Pharmaceuticals (XENE), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Bausch Health Cos (BHC), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

Autolus Therapeutics vs. Its Competitors

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

31.8% of AMNEAL PHARMACEUTICALS shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 26.6% of AMNEAL PHARMACEUTICALS shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AMNEAL PHARMACEUTICALS has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than AMNEAL PHARMACEUTICALS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMNEAL PHARMACEUTICALS$2.79B1.05-$116.89M$0.01939.00
Autolus Therapeutics$10.12M48.65-$220.66M-$0.84-2.20

AMNEAL PHARMACEUTICALS has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

AMNEAL PHARMACEUTICALS has a net margin of 0.12% compared to Autolus Therapeutics' net margin of 0.00%. Autolus Therapeutics' return on equity of -56.18% beat AMNEAL PHARMACEUTICALS's return on equity.

Company Net Margins Return on Equity Return on Assets
AMNEAL PHARMACEUTICALS0.12% -189.49% 6.17%
Autolus Therapeutics N/A -56.18%-29.61%

AMNEAL PHARMACEUTICALS presently has a consensus target price of $11.60, suggesting a potential upside of 23.54%. Autolus Therapeutics has a consensus target price of $9.12, suggesting a potential upside of 392.97%. Given Autolus Therapeutics' higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than AMNEAL PHARMACEUTICALS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMNEAL PHARMACEUTICALS
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Autolus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Autolus Therapeutics had 7 more articles in the media than AMNEAL PHARMACEUTICALS. MarketBeat recorded 18 mentions for Autolus Therapeutics and 11 mentions for AMNEAL PHARMACEUTICALS. Autolus Therapeutics' average media sentiment score of 0.77 beat AMNEAL PHARMACEUTICALS's score of 0.48 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMNEAL PHARMACEUTICALS
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Autolus Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AMNEAL PHARMACEUTICALS and Autolus Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AUTL vs. The Competition

MetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$489.70M$3.10B$5.61B$9.84B
Dividend YieldN/A2.23%4.61%4.07%
P/E Ratio-2.2020.4930.2925.74
Price / Sales48.65356.37463.41115.83
Price / CashN/A43.0338.2159.48
Price / Book1.428.608.826.15
Net Income-$220.66M-$54.65M$3.25B$265.06M
7 Day Performance-20.60%5.86%3.70%2.60%
1 Month Performance-25.70%8.86%5.84%2.83%
1 Year Performance-50.67%13.33%29.92%25.58%

Autolus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AUTL
Autolus Therapeutics
3.0217 of 5 stars
$1.85
+0.5%
$9.12
+393.0%
-48.5%$489.70M$10.12M-2.20330News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
AMRX
AMNEAL PHARMACEUTICALS
3.054 of 5 stars
$7.96
+1.7%
$11.60
+45.7%
+20.2%$2.45B$2.79B13.278,100News Coverage
Insider Trade
NAMS
NewAmsterdam Pharma
3.5361 of 5 stars
$21.66
+1.8%
$41.30
+90.7%
+48.1%$2.39B$45.56M0.004
XENE
Xenon Pharmaceuticals
2.0303 of 5 stars
$33.16
+8.7%
$54.82
+65.3%
-1.9%$2.34B$9.43M0.00210Trending News
Earnings Report
Analyst Forecast
Analyst Revision
High Trading Volume
KNSA
Kiniksa Pharmaceuticals International
2.6464 of 5 stars
$32.95
+3.0%
$41.17
+24.9%
+30.8%$2.33B$423.24M799.50220Positive News
Insider Trade
RXRX
Recursion Pharmaceuticals
1.4777 of 5 stars
$5.80
+2.1%
$7.00
+20.7%
-10.2%$2.31B$58.84M0.00400Gap Down
CNTA
Centessa Pharmaceuticals
2.6345 of 5 stars
$16.08
-4.3%
$28.10
+74.8%
+40.0%$2.25B$6.85M0.00200Earnings Report
Analyst Forecast
ARWR
Arrowhead Pharmaceuticals
4.1504 of 5 stars
$16.47
+3.4%
$43.71
+165.4%
-17.3%$2.20B$3.55M-11.76400Trending News
Earnings Report
Analyst Forecast
Analyst Revision
IDYA
IDEAYA Biosciences
4.4495 of 5 stars
$25.00
+3.0%
$48.09
+92.4%
-33.7%$2.13B$7M0.0080
BHC
Bausch Health Cos
4.1629 of 5 stars
$5.78
+1.1%
$9.00
+55.8%
+35.8%$2.11B$9.63B1.5220,700News Coverage
Insider Trade
BLTE
Belite Bio
2.7327 of 5 stars
$69.79
+6.2%
$96.67
+38.5%
+38.2%$2.09BN/A0.0010News Coverage
Earnings Report
Analyst Revision

Related Companies and Tools


This page (NASDAQ:AUTL) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners